Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

Phase IB Trial of Metformin, Digoxin, Simvastatin in Subjects With Advanced Pancreatic Cancer and Other Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03889795
• Other study ID #: C3
• Status: Recruiting
• Phase: Phase 1
• Start date: June 5, 2019
• Est. completion date: December 30, 2026

Study information

• Verified date: May 2024
• Source: University of Toledo
• Contact: Danielle Mockensturm
• Phone: 419-383-6925
• Email: danielle.mockensturm[@]utoledo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center trial in subjects with pancreatic cancer and other advanced solid tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and showing disease progression on established standard therapy, will be enrolled in this trial.

Description:

This is a single-center trial in subjects with pancreatic cancer and other advanced solid tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and showing disease progression on established standard therapy, will be enrolled in this trial.

C3 (Simvastatin + Digoxin + Metformin) will be given as three oral pills within recommended package insert safe levels. Subjects will be accrued in 3-subject dose escalation cohorts. 3 additional subjects will be treated at the presumptive maximum effective cohort dose/schedule for a total of 6 subjects at maximum effective level.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: December 30, 2026
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Subject =18 years with histologically confirmed solid tumor.

2. Dose expansion subjects must have at least one tumor mass amenable to core needle biopsy.

3. Refractory or intolerant to established standard of care.

4. Have at least one tumor mass amenable to core needle biopsy. Adequate Archival Tissue required for patients that will take part in the dose escalation cohorts.

5. ECOG performance status (PS) = 0-2, or Karnofsky PS =60%, or Lansky PS =60%.

6. Normal organ and marrow function: absolute granulocyte count =1,000/mm3, absolute lymphocyte count =400/mm3, platelets =100,000/mm3, total bilirubin = institutional upper normal limit, AST/ASL =2x institutional upper limit of normal, GFR >60 mL/min/1.73 m2 and creatinine <1.5 mg/dL.

7. Subject has recovered to CTCAE Grade 1 or better from all adverse events associated with prior therapy or surgery. Pre-existing motor or sensory neurologic pathology or symptoms must be recovered to CTCAE Grade 2 or better.

8. If female of childbearing potential, has a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a negative serum test will then be required for study entry.

9. Ability to understand and the willingness to sign a written informed protocol specific consent.

Exclusion Criteria:

1. Anti-cancer chemotherapy, biologic therapy or immunotherapy within 3 weeks or radiation therapy within 2 weeks of first infusion.

2. Known history of other malignancy unless having undergone curative intent therapy without evidence of that disease for = 3 years except cutaneous squamous cell and basal cell skin cancer, superficial bladder cancer, in situ cervical cancer or other in situ cancers are allowed if definitively resected.

3. Patients with only PET non-avid disease.

4. Brain metastases unless treated with curative intent (gamma knife or surgical resection) and without evidence of progression for = 2 months.

5. Known history of rhabdomyolysis.

6. History of or current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the Investigator.

7. Known HIV or chronic Hepatitis B or C infection.

8. Have signs and symptoms consistent with an active infection.

9. Live vaccination for the prevention of infectious disease administered <30 days prior to the start of study therapy or inactivated vaccination <14 days prior to the start of study therapy.

10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to Metformin, Simvastatin, and/or Digoxin.

11. Patients diagnosed with Wolff-Parkinson-White Syndrome or electrocardiographic (ECG) pattern. Other cardiac conditions including: Previous MI with evidence of residual electrographic pattern consisted with bradycardia/heart block. Atrio-ventricular (AV) heart block (currently ongoing). History of ventricular fibrillation. Sick Sinus Syndrome or Sinus bradycardia thought to be caused by sinus node disease, unless effectively treated. Heart failure associated with preserved left ventricular ejection fraction, including constructive pericarditis, restrictive cardiomyopathy, and Amyloid heart muscle disease.

12. Women of childbearing potential who are found to be pregnant as evidenced by positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) or nursing.

Related Conditions & MeSH terms

• Advanced Pancreatic Cancer
• Advanced Solid Tumor
• Pancreatic Neoplasms

Intervention

Drug:
• Metformin
Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
• Simvastatin
Simvastatin oral pill will be taken daily in the evening.
• Digoxin
Digoxin oral pill will be taken once daily.

Locations

Country	Name	City	State
United States	University of Toledo, Eleanor N. Dana Cancer Center	Toledo	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Danae Hamouda, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range	Occurrence of any = Grade 3 toxicity encountered within the four weeks following the administration of C3, regardless of attribution	Up to one year
Secondary	Safety and Tolerability: Occurrence of treatment - emergent adverse events (TEAEs) and other abnormalities	Occurrence of treatment - emergent adverse events (TEAEs) and occurrence of abnormalities in laboratory test values, markedly abnormal vital sign measurements, and clinically significant abnormal electrocardiograms (ECGs), including conduction abnormalities and changes in QT interval	Up to 2 years
Secondary	Efficacy (Disease Response)	Response and progression evaluated using Response Evaluation criteria in solid tumors	Up to 2 years
Secondary	Assess BIRC5 levels of expression in tumor tissue	Blood samples for pharmacokinetic analysis of C3 will be collected at designated time points.	RNA and protein levels of expression at baseline and at 2 months after C3 treatment
Secondary	Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment	Molecular signal tumor blood (plasma) and microenvironment protein expression patterns via quantitative mass spectrometry.	Baseline and at 2 months